Yang Yang, Zhang Danhong, Zhou Xia, Bao Wuan, Ji Yonglin, Sheng Liming, Cheng Lei, Chen Ying, Du Xianghui, Qiu Guoqin
Department of Radiation Therapy, Zhejiang Cancer Hospital, Hangzhou, China; Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, China.
J Cancer. 2018 Jan 1;9(2):433-439. doi: 10.7150/jca.21465. eCollection 2018.
The use of PCI in early operable patients with small cell lung cancer (SCLC) is still controversial. Therefore, we conducted a systematic review with meta-analysis to investigate the effects of PCI in resected SCLC patients. Relevant studies were identified from PubMed and EMBASE databases, the pooled hazard risks were obtained by the random-effects model. We also analyzed the brain metastasis (BM) risk in p-stage I patients without PCI. Five retrospective studies were identified and a total of 1691 patients were included in our analysis, 315 of them received PCI. For all the resected patients, PCI was associated with improved overall survival (HR: 0.52, 95% CI: 0.33-0.82), and reduced brain metastasis risk (RR: 0.50, 95%CI: 0.32-0.78). However, with regard to p-stage I patients, no survival benefit was brought by PCI (HR: 0.87, 95% CI: 0.34-2.24). Moreover, the pooled analysis of 7 studies found that the 5-year brain metastasis risk was relatively low (12%, 95% CI: 8%-17%) for p-stage I patients without PCI. PCI might be associated with a favorable survival advantage and reduced BM risk in complete resected SCLC patients, except for p-stage I patients.
对于早期可手术的小细胞肺癌(SCLC)患者,使用预防性脑照射(PCI)仍存在争议。因此,我们进行了一项系统评价和荟萃分析,以研究PCI对手术切除的SCLC患者的影响。从PubMed和EMBASE数据库中检索相关研究,采用随机效应模型获得合并风险比。我们还分析了未接受PCI的Ⅰ期患者发生脑转移(BM)的风险。共纳入5项回顾性研究,总计1691例患者,其中315例接受了PCI。对于所有手术切除的患者,PCI与总生存期改善相关(风险比:0.52,95%可信区间:0.33-0.82),且脑转移风险降低(风险比:0.50,95%可信区间:0.32-0.78)。然而,对于Ⅰ期患者,PCI未带来生存获益(风险比:0.87,95%可信区间:0.34-2.24)。此外,对7项研究的汇总分析发现,未接受PCI的Ⅰ期患者5年脑转移风险相对较低(12%,95%可信区间:8%-17%)。除Ⅰ期患者外,PCI可能会给完全切除的SCLC患者带来生存优势并降低BM风险。